Sciele Pharma, Inc. (SCRX), a specialty pharmaceutical company, engages in the development, marketing, and sale of prescription products for the treatment of cardiovascular, metabolic, obstetrical and gynecological, and pediatric and gastroenterological conditions and disorders. Scieles products include Sular, an antihypertensive prescription medication Nitrolingual spray for acute relief or prevention of chest pain associated with angina pectoris that results from heart disease for curing acute angina Prenate Elite and Optinate prescription prenatal vitamin products Robinul and Robinul Forte for adjunctive therapy for peptic ulcer and Ponstel for the relief of mild to moderate pain for patients of 14 years of age and older from dysmenorrheal, which is pain associated with menstruation. And finally, Triglide, a novel treatment for lipid disorders and elevated cholesterol levels.

Sciele has been pretty active on the acquisition front over the past couple of years. In 2005 Sciele acquired two products from Andrx Pharmaceuticals: Fortamet, an extended release tablet of metformin HCl for type-II diabetes, and Altoprev, a branded lovastatin for cholesterol management. In July 2007, Sciele acquired LARx, an innovative head lice asphyxiation product, developed by Summers Laboratories, Inc. for the U.S., Canada and Mexico and entered into an exclusive marketing agreement for Clonicel with Addrenex Pharmaceuticals. In June 2007, Sciele acquired privately held Alliant Pharmaceuticals Inc. for approximately $109.75 million in cash, including approximately $14 million in debt. With this acquisition, Sciele gained five products that are currently available in the pediatric market. Finally, in March 2008, Sciele acquired the Twinject epinephrine auto-injector from Verus Pharmaceuticals. SCRX sells its products to pharmaceutical wholesalers, chain drug stores, and other retail merchandisers, as well as directly to pharmacies. The company is based in Atlanta, Georgia and employs roughly 920 people worldwide.